Apogee Therapeutics (APGE) Cash from Operations (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Cash from Operations data on file, last reported at 55600000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations fell 14.69% year-over-year to 55600000.0 in Q1 2026; TTM through Mar 2026 was 234623000.0, a 24.79% decrease from a year earlier, with the FY2025 full-year figure at 227500000.0, down 32.91% from the prior year.
• Cash from Operations for Q1 2026 stood at 55600000.0, up from 62739000.0 in the prior quarter.
• Over the last five years, Cash from Operations for APGE reached as high as 9189000.0 in Q4 2022 and fell as low as 67714000.0 in Q4 2024.
• Historically, Cash from Operations has averaged 38444571.43 across 5 years, with a median of 37080000.0 in 2024.
• Across the five-year window, Cash from Operations sank 223.8% in 2023 and increased 7.35% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 9189000.0 in 2022, then sank by 223.8% to 29754000.0 in 2023, then tumbled by 127.58% to 67714000.0 in 2024, then gained by 7.35% to 62739000.0 in 2025, then gained by 11.38% to 55600000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 55600000.0 in Q1 2026, 62739000.0 in Q4 2025, and 54261000.0 in Q3 2025.